on INVENTIVA (EPA:IVA)
Inventiva Announces its First Quarter 2026 Financial Results
The biopharmaceutical company Inventiva has published its financial results for the first quarter of 2026, with cash and cash equivalents amounting to €75 million. Short-term deposits reached €121.5 million. By comparison, at the end of 2025, these figures were €99.3 million and €131.6 million, respectively.
Inventiva recorded no revenue for the quarter in question, mirroring the previous year's figures. The company anticipates that its current financial resources could be sufficient to support its operations until mid-quarter 2027. The potential exercise of warrants could extend this support until mid-quarter 2027.
Investors are awaiting the main results of the NATiV3 study in the fourth quarter of 2026. Inventiva is scheduled to participate in several international conferences in the coming months to strengthen its position in the biopharmaceutical sector.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news